CHARLOTTE, N.C., June 18, 2025 /PRNewswire/ -- Nucor Corporation (NYSE: NUE) today announced guidance for its second quarter ending July 5, 2025. Nucor expects second quarter earnings to be in the range of $2.55 to $2.65 per diluted share. Nucor reported net earnings of $0.67 per diluted share in the first quarter of 2025 and $2.68 per diluted share in the second quarter of 2024.Second Quarter of 2025 CommentaryEarnings in the second quarter of 2025 are expected to increase across all three of our operating ...

Zefiro subsidiary P&G continues to work with government agencies as a trusted service provider for projects involving several aspects of environmental remediation.FORT LAUDERDALE, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the “Company”, “Zefiro”, or “ZEFI”) is pleased to announce that its wholly owned subsidiary, Plants & Goodwin, Inc. (“P&G”), has been selected as the prime contractor for a three-year Construction Manager at Risk (“CMA ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Bio ...

MONTREAL and LYON, France, June 18, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is proud to announce that its French technology partner, NOVACIUM SAS ("Novacium"), has launched the industrial production of cylindrical lithium-ion battery cells incorporating its third-generation silicon-based anode material ("GEN3"). Following the press releases dated Ju ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer  FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric clinical study Enrollment and dosing are ongoing in pivotal, adaptive design Phase 3 MIRACLE trial of Annamycin in adult patients with R/R AML; Initial data readout is on track for the second half of 2025 HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculi ...

Investor Presentation May 2025 Disclaimers and Forward-Looking Statements This investor presentation (this "presentation") and any oral statements made in connection with this presentation are for information purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other securities of Aveanna Healthcare Holdings Inc. (including its consolidated subsidiaries, "Aveanna," the "Company," "we," "us" or "our"). The information con ...

Translating cancer biology into medicines Cyclacel Pharmaceuticals, Inc. (CYCC) NOVEMBER 2024 Disclaimer This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward- looking statements. Such forward-looking statements include, among other things, statements related to the efficacy and safety profile of fadraciclib in an inco ...

MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the "Corporation"), is pleased to announce that at its annual general meeting of shareholders held on June 17, 2025, all nominees listed in the management proxy circular were elected. 1. Election of Directors The following persons have been nominated as directors of Dynacor to hold office until the next meeting of shareholders, or until their successors are elected or appointed. Detailed results are as below: NomineeVote ...

股东方面，截至2025年3月31日，春立医疗股东户数7167户，较上次增加501户，户均持股市值35.28万 元，户均持股数量2.76万股。 北京市春立正达医疗器械股份有限公司的主营业务是植入性骨科医疗器械的研发、生产与销售。公司的 主要产品是脊柱类、创伤类、关节类、运动医学类、骨修复材料类植入物、手术器械产品、富血小板血 浆（PRP）制备用套装、封闭创伤负压引流套装。2024年获国家工信部认定的人工关节假体制造业单项 冠军企业。 6月18日，春立医疗今日收盘16.49元，下跌2.54%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到49.47倍，总市值63.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.10倍，行业中值36.43倍，春立医疗排 名第88位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比3.60%；净利润5807.11万元，同 比5.20%，销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗49.4750.612.2063.25亿行业平均 49.1047.114.54105.10亿行业中 ...

经营范围含新能源汽车生产测试设备销售，光伏设备及元器件销售，煤炭及制品销售，充电桩销售，非 金属矿及制品销售，化工产品销售（不含许可类化工产品），润滑油销售，建筑材料销售，电子产品销 售，日用百货销售，机械电气设备销售，金属材料销售，办公用品销售，橡胶制品销售，塑料制品销 售，电气设备销售，再生资源销售，通讯设备销售，电工器材销售，灯具销售，泵及真空设备销售，包 装材料及制品销售，建筑用钢筋产品销售，五金产品批发，厨具卫具及日用杂品批发，劳务服务（不含 劳务派遣），供应链管理服务，储能技术服务，信息咨询服务（不含许可类信息咨询服务），普通货物 仓储服务（不含危险化学品等需许可审批的项目），土石方工程施工，国内货物运输代理，国内贸易代 理（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 天眼查App显示，近日，江西鸿涌新能源有限公司成立，法定代表人为刘国军，注册资本2000万人民 币，由中鸿新能源科技（江西）有限公司全资持股。 序号股东名称持股比例1中鸿新能源科技（江西）有限公司100% 企业名称江西鸿涌新能源有限公司法定代表人刘国军注册资本2000万人民币国标行业电力、热力、燃气 及水生产和供应业> ...